Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

被引：0
|
作者：
Aleksi Tornio
Mikko Niemi
Pertti J. Neuvonen
Janne T. Backman
机构：
[1] University of Helsinki,Department of Clinical Pharmacology
来源：
European Journal of Clinical Pharmacology | 2007年 / 63卷
关键词：
CYP2C8; Drug interaction; Gemfibrozil; Ibuprofen enantiomers; Stereoselectivity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：463 / 469
页数：6
相关论文
共 50 条
  • [1] Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
    Tornio, Aleksi
    Niemi, Mikko
    Neuvonen, Pertti J.
    Backman, Janne T.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (05) : 463 - 469
  • [2] Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters
    Tornio, Aleksi
    Neuvonen, Pertti J.
    Niemi, Mikko
    Backman, Janne T.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (01) : 83 - 95
  • [3] The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (02) : 151 - 155
  • [4] The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast
    Tiina Karonen
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2011, 67 : 151 - 155
  • [5] Unlike gemfibrozil glucuronide, clopidogrel glucuronide is not a potent inhibitor of CYP2C8
    Yerino, Phyllis
    Toren, Paul
    Ogilvie, Brian W.
    Parkinson, Andrew
    DRUG METABOLISM REVIEWS, 2006, 38 : 124 - 125
  • [6] The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone
    Tornio, Aleksi
    Neuvonen, Pertti J.
    Backman, Janne T.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (08) : 645 - 651
  • [7] The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone
    Aleksi Tornio
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2006, 62
  • [8] Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone
    Aquilante, Christina L.
    Kosmiski, Lisa A.
    Bourne, David W. A.
    Bushman, Lane R.
    Daily, Elizabeth B.
    Hammond, Kyle P.
    Hopley, Charles W.
    Kadam, Rajendra S.
    Kanack, Alexander T.
    Kompella, Uday B.
    Le, Merry
    Predhomme, Julie A.
    Rower, Joseph E.
    Sidhom, Maha S.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (01) : 217 - 226
  • [9] Underlying mechanism of drug-drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8
    Takagi, Motoi
    Sakamoto, Masaya
    Itoh, Tomoo
    Fujiwara, Ryoichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2015, 30 (04) : 288 - 294
  • [10] Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses
    Honkalammi, Johanna
    Niemi, Mikko
    Neuvonen, Pertti J.
    Backman, Janne T.
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (10) : 1977 - 1986
12345